

Ref: FOI/GS/ID 9245

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone, Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net
www.mtw.nhs.uk

14 August 2024

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Endometrial Cancer.

You asked: All questions are shown as received by the Trust.

Q1. Does your trust provide SACT (systemic anti-cancer therapy) treatments for endometrial cancer? If not, which other trust do you refer endometrial cancer patients to for SACT treatments?

Q2. How many patients were treated for endometrial cancer (any stage) in the past three months with the following treatments:

- a. Dostarlimab (Jemperli)*
- b. Dostarlimab (Jemperli) AND Chemotherapy*
- c. Hormone therapy (Progesterone or Letrozole)*
- d. Pembrolizumab (Keytruda) monotherapy*
- e. Lenvatinib + Pembrolizumab (Lenvima +Keytruda)*
- f. Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide)*
- g. Any other SACT*

Q3. In the past three months, how many patients were treated for recurrent endometrial cancer after having previously received platinum-based chemotherapy?

Q4. In the past three months, how many patients were treated for endometrial cancer with the following as first line treatments:

- a. Dostarlimab (Jemperli) AND Chemotherapy*
- b. Hormone therapy (Progesterone or Letrozole)*
- c. Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide)*
- d. Any other SACT*

Q5. Does your trust participate in any clinical trials for the treatment of endometrial cancer? If so, can you please provide the name of each trial and the number of patients taking part.

Trust response:

Q1. Yes

Q2.

a. 2

b. 0

c. 0

d. 0

e. 2

f. 16

g. 4

Q3. 7

Q4. The Trust is unable to provide this data. The Trust system does not record whether a SACT treatment is first line or not. It does not record hormone therapy treatment.

Q5. None at this time.